Abstract:The recognition of nucleic acids by the innate immune system during viral infection results in the production of type I interferons and the activation of antiviral immune responses. The RNA helicases RIG-I and MDA-5 recognize distinct types of cytosolic RNA species and signal through the mitochondrial protein MAVS to stimulate the phosphorylation and activation of the transcription factors IRF3 and IRF7, thereby inducing type I interferon expression. Alternatively, the activation of NF-kappaB leads to proinflammatory cytokine production. The function of MAVS is dependent on both its C-terminal transmembrane (TM) domain and N-terminal caspase recruitment domain (CARD). The TM domain mediates MAVS dimerization in response to viral RNA, allowing the CARD to bind to and activate the downstream effector TRAF3. Notably, dimerization of the MAVS CARD alone is sufficient to activate IRF3, IRF7, and NF-kappaB. However, TRAF3-deficient cells display only a partial reduction in interferon production in response to RNA virus infection and are not defective in NF-kappaB activation. Here we find that the related ubiquitin ligase TRAF5 is a downstream target of MAVS that mediates both IRF3 and NF-kappaB activation. The TM domain of MAVS allows it to dimerize and thereby associate with TRAF5 and induce its ubiquitination in a CARD-dependent manner. Also, NEMO is recruited to the dimerized MAVS CARD domain in a TRAF3 and TRAF5-dependent manner. Thus, our findings reveal a possible function for TRAF5 in mediating the activation of IRF3 and NF-kappaB downstream of MAVS through the recruitment of NEMO. TRAF5 may be a key molecule in the innate response against viral infection.

The mitochodnrial E3 ligase MARCH5 resolves RIG-I and MAVS aggregates in innate immunity

The mitochondrial E3 ubiquitin ligase MARCH5 resolves MAVS aggregates during antiviral signaling.

The mitochondrial ubiquitin ligase MARCH5 resolves MAVS aggregates during antiviral signalling

MAVS O-GlcNAcylation is Essential for Host Antiviral Immunity Against Lethal RNA Viruses.

TRAF5 is a downstream target of MAVS in antiviral innate immune signaling

MAVS-loaded unanchored Lys63-linked polyubiquitin chains activate the RIG-I-MAVS signaling cascade

MDA5 ISGylation is crucial for immune signaling to control viral replication and pathogenesis

Regulation of MAVS activation through post-translational modifications

Trim65-Catalized Ubiquitination is Essential for Mda5-Mediated Antiviral Innate Immunity

MAVS ubiquitination by the E3 ligase TRIM25 and degradation by the proteasome is involved in type I interferon production after activation of the antiviral RIG-I-like receptors

Virus Infection Triggers MAVS Polymers of Distinct Molecular Weight

Key role of Ubc5 and lysine-63 polyubiquitination in viral activation of IRF3.

MicroRNA-33/33* Inhibit the Activation of MAVS Through AMPK in Antiviral Innate Immunity

Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3

Identification and Characterization of MAVS, a Mitochondrial Antiviral Signaling Protein that Activates NF-κB and IRF3

MAVS Cys508 palmitoylation promotes its aggregation on the mitochondrial outer membrane and antiviral innate immunity

MAVS Promotes Inflammasome Activation by Targeting ASC for K63-Linked Ubiquitination via the E3 Ligase TRAF3.

Structural and biochemical studies of RIG-I antiviral signaling

The Mitochondrial Shuttle Protein ERAL1 Amplifies Antiviral Immune Responses

Palmitoylation acts as a checkpoint for MAVS aggregation to promote antiviral innate immune responses

Upstream ORFs Prevent MAVS Spontaneous Aggregation and Regulate Innate Immune Homeostasis